GeoVax develops vaccines and immunotherapies against infectious diseases and solid tumor cancers. It last closed at $1.97 on Nov 17, down 4.37% on the day.
Only 1 firm rated GOVX in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 407.6% upside
Based on 1 analyst who set a price target on GOVX in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $1.97.
Low $10.00Avg $10.00High $10.00
Blue marker: last close $1.97
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
Noble Capital MarketsMaintained
Sep 15Buy$10
Date
Firm
Action
Rating
Price target
Sep 15
Noble Capital Markets
Maintained
Buy
$10
Loading…
Technical Analysis
GOVX · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend, overbought
The stock is 68% above its 20 day and 77% above its 50 day average. It is 42% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 77), overbought. The nearest support is the Pivot at $1.93, and the nearest resistance the Pivot R1 at $2.12.
Short trendBullish
Long trendBearish
MomentumStrong
StretchOverbought
VolatilityHigh, 14.7%/day
Key levels
$11.2852 week high+472.6%
$3.00Swing high (Nov 11)+52.3%
$2.12Pivot R1+7.6%
$1.97Last close
$1.93Pivot−2.0%
$1.78Pivot S1−9.6%
$1.17Swing low (Jun 24)−40.6%
$1.14200 day average−42.1%
$0.64100 day average−67.5%
$0.6320 day average−68.0%
$0.4550 day average−77.2%
$0.1152 week low−94.4%
Indicators
RSI (14)
76.51
Overbought above 70
Overbought
MACD
0.41
Above its signal line
Bullish
Stochastic
62.3
Middle of its range
Neutral
ADX (14)
45.7
Strong uptrend
Williams %R
-35.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
125.8
Oversold below −100, overbought above 100
Overbought
Rate of change
+1100.5%
Change over 10 sessions
Bullish
ATR (14)
$0.29
Typical daily range, 14.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Bounce inside a longer downtrend, nearing overbought
Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityHigh, 28.2%/day
Key levels
$11.2852 week high+472.6%
$3.00Swing high (Nov 11)+52.3%
$2.12Pivot R1+7.6%
$1.97Last close
$1.93Pivot−2.0%
$1.78Pivot S1−9.6%
$1.17Swing low (Jun 24)−40.6%
$1.14200 day average−42.1%
$0.64100 day average−67.5%
$0.6320 day average−68.0%
$0.4550 day average−77.2%
$0.1152 week low−94.4%
Indicators
RSI (14)
58.22
Middle of its range
Neutral
MACD
-0.45
Above its signal line
Bullish
Stochastic
40.7
Middle of its range
Neutral
ADX (14)
28.0
Trending up
Williams %R
-35.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
234.1
Oversold below −100, overbought above 100
Overbought
Rate of change
+325.5%
Change over 10 sessions
Bullish
ATR (14)
$0.56
Typical daily range, 28.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for GOVX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how GOVX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90D
No whale options trades in GOVX in the last 90 days.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GOVX is in one of them and how their past GOVX trades turned out.
GeoVax is a biotechnology company based in Smyrna, Georgia, that develops vaccines and immunotherapies for infectious diseases and solid tumor cancers. Its lead near-term effort is a vaccine candidate against mpox and smallpox, intended to address supply shortages of orthopoxvirus vaccines for public health agencies and biodefense programs. The company also develops Gedeptin, a gene therapy for solid tumors including head and neck cancer, and a COVID-19 vaccine candidate for people with weakened immune systems.